


Zongertinib

Chemical Properties

CAS No. :	2728667-27-2
Formula:	C ₂₉ H ₂₉ N ₉ O ₂
Molecular Weight:	535.6
Storage:	Powder: -20°C for 3 years In solvent: -80°C for 1 year Actual storage temperature shall be subject to the COA.



Biological Description

Description	Zongertinib (BI 1810631) is a HER2 inhibitor, a selective HER2 tyrosine kinase inhibitor (with IC ₅₀ values of 13 nM and 579 nM for HER2 and EGFR, respectively), featuring covalent binding properties, used for solid tumor research.
Targets(IC ₅₀)	HER,c-Met/HGFR,Tyrosine Kinases
In vitro	Methods: Phosphorylation assays were performed in HEK cells, and proliferation assays were conducted in Ba/F3 cells. Results: Zongertinib demonstrated high potency against HER2 YVMA with selectivity over wild-type EGFR; in Ba/F3 cells, its inhibitory effect on HER2 YVMA was 100-fold higher than that on wild-type EGFR. [1]
In vivo	Methods: In NCI-N87 (HER2-amplified) and PC-9 HER2YVMA CDX and PDX models, Zongertinib (5-50 mg/kg) was administered orally once daily, alone or in combination with T-DXd, T-DM1, or adagrasib, for 21-60 consecutive days. Results: Zongertinib alone significantly inhibited tumor growth, and combination with ADCs or KRASG12C inhibitors synergistically enhanced anti-tumor activity with good tolerability. [2]

Solubility Information

Solubility	DMSO: 45.91 mg/mL (85.72 mM),Sonication is recommended. (< 1 mg/ml refers to the product slightly soluble or insoluble)
In vivo Formulation	10% DMSO+40% PEG300+5% Tween-80+45% Saline: 2 mg/mL (3.73 mM),Sonication is recommended. <i>Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.</i>

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	1.8671 mL	9.3353 mL	18.6706 mL
5 mM	0.3734 mL	1.8671 mL	3.7341 mL
10 mM	0.1867 mL	0.9335 mL	1.8671 mL
50 mM	0.0373 mL	0.1867 mL	0.3734 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Reference

Brazel, Danielle et al. The development of Zongertinib for HER2-mutant NSCLC. Critical reviews in oncology/hematology vol. 215 (2025): 104896.

Birgit Wilding, et al. Zongertinib (BI 1810631), an Irreversible HER2 TKI, Spares EGFR Signaling and Improves Therapeutic Response in Preclinical Models and Patients with HER2-Driven Cancers. Cancer Discov 1 January 2025; 15 (1): 119-138.

Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel: 781-999-4286 E_mail: info@targetmol.com Address: 34 Washington Street, Wellesley Hills, MA 02481